Replies to post #191303 on NorthWest Biotherapeutics Inc (NWBO)

[j e d]

Rintega's control arm had a mOS of 23 months. Other clinical trials also had well above historical (17 mo) due to selection/enrollment criteria. I'm wondering why we think NWBO will be any different, considering there was significant enrollment criteria for dcvax as well.